Last reviewed · How we verify
NCT06850454
Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy
Phase 3 trial testing olanzapine in Chemotherapy Induced Nausea and Vomiting in 140 participants. Currently enrolling.
10 January 2026
Quick facts
| Lead sponsor | Mahidol University |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | supportive care |
| Enrollment | 140 |
| Start date | 10 January 2025 |
| Primary completion | 10 January 2026 |
| Estimated completion | 31 January 2026 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- olanzapine (olanzapine) — full drug profile →
- Placebo
Conditions studied
- Chemotherapy Induced Nausea and Vomiting — all drugs for Chemotherapy Induced Nausea and Vomiting →
Sponsor
Mahidol University
Who can join
18 and older, any sex, with Chemotherapy Induced Nausea and Vomiting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06850454
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of olanzapine
Trials testing the same drug.
- NCT06600477 — A Study of Olanzapine After Intranasal and Intramuscular Administration · Phase 1 · completed
- NCT03557931 — A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schiz · Phase 2 · completed
- NCT02708394 — Molecular Mechanisms of Antipsychotic-induced Insulin Resistance · EARLY_PHASE1 · completed
- NCT00149292 — Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo · Phase 2 · completed
- NCT00156117 — Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933) · Phase 3 · completed
Other recruiting trials for Chemotherapy Induced Nausea and Vomiting
Currently open trials in the same condition.
- NCT06886451 — Vomiting Prevention in Children With Cancer · NA · recruiting
- NCT06756022 — Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia · recruiting
Other Mahidol University trials
Trials by the same sponsor.
- NCT07568496 — Greater Occipital Nerve Block for Migraine With Medication Overuse Headache · NA · not yet recruiting
- NCT07407400 — Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients · Phase 4 · not yet recruiting
- NCT07378501 — Thai Version of the Pediatric Quality of Recovery Score (PedSQoR): Translation and Psychometric Validation Study · not yet recruiting
- NCT07438301 — Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration · not yet recruiting
- NCT07390006 — Enabling Patient-Reported Outcomes Through Innovative Care - ACS (EPIC-ACS) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06850454 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mahidol University
- Last refreshed: 27 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06850454.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing